Moleculin Biotech (MBRX) Projected to Post Quarterly Earnings on Monday

Moleculin Biotech (NASDAQ:MBRX) is projected to issue its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($1.69) per share for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Moleculin Biotech Stock Performance

NASDAQ MBRX traded down $0.04 on Monday, reaching $2.48. The stock had a trading volume of 50,592 shares, compared to its average volume of 153,414. Moleculin Biotech has a 12-month low of $1.79 and a 12-month high of $28.61. The business’s 50-day moving average price is $2.34 and its 200 day moving average price is $5.30. The stock has a market cap of $13.22 million, a P/E ratio of -0.08 and a beta of 1.74.

Institutional Investors Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent reporting period. Institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

MBRX has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective on shares of Moleculin Biotech in a research note on Tuesday, March 24th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Moleculin Biotech has an average rating of “Hold” and an average price target of $22.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.